Gland Pharma Ltd, a global pharmaceutical manufacturer specializing in generic sterile injectables, saw its shares decline by more than 2% during Wednesday's trading session. The stock hit an intraday low of Rs 2,924.60, a notable drop from its previous closing price of Rs 2,988.60. The day began with the stock opening at Rs 3,004.45, also reaching this as its intraday high.
Significant Block Deal Valued at ₹450 Crore
The share price movement was largely influenced by reports of a substantial block deal. Approximately 15 lakh shares of Gland Pharma were expected to change hands, with the total transaction value estimated at around Rs 450 crore. According to a report by CNBC Awaaz, the floor price for this block deal was fixed at Rs 2,990 per share, which was close to the stock's previous day's closing price.
This block deal activity comes at a time when Gland Pharma's stock has shown considerable gains throughout the year. So far in 2026, the company's shares have appreciated by 72.99%, marking a rise of Rs 1,251.90 year-to-date.
Analyst Outlook Remains Positive
Despite today's dip, brokerage firm 360 One Capital has maintained a positive stance on Gland Pharma. The firm has set a target price of Rs 3,050 per share, citing strong growth prospects for the company's Contract Development and Manufacturing Organization (CDMO) business.
- CDMO Business Growth: 360 One Capital anticipates approximately 20% constant-currency growth as the CDMO segment expands.
- EBITDA Margin Improvement: The brokerage projects an improvement in EBITDA margins, expecting them to reach around 34-35% from the current level of approximately 28%.
- Financial Projections: The firm forecasts a 13% Revenue CAGR and a 21% PAT CAGR for Gland Pharma over fiscal years 2026-2028. At a CMP of Rs 2,922, Gland Pharma is currently trading at 39x FY27 EPS of Rs 75.1 and 31x FY28 EPS of Rs 93.1.